Neuropeptide Y counteracts interferon-alpha-induced anorexia

NeuroImmunoModulation

Volumn 6, Issue 5, 1999, Pages 361-366

  Turrin, Nicolas P ^a   Flynn, Mark C ^a   Plata Salamán, Carlos R ^a,b  

^a UNIVERSITY OF DELAWARE   (United States)

^b R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Antagonism; Brain; Cerebrospinal fluid; Cytokine; Feeding; Food intake; Immunotherapy; Intracerebroventricular microinfusion; Neuroimmunology

Indexed keywords

ALPHA INTERFERON; NEUROPEPTIDE Y;

ANIMAL EXPERIMENT; ANOREXIA; ARTICLE; BRAIN THIRD VENTRICLE; DOSE RESPONSE; DRUG EFFECT; FEEDING BEHAVIOR; IMMUNOMODULATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; NEUROIMMUNOLOGY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032871173     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026396     Document Type: Article

References (44)

1. Kalvakolanu DV, Borden EC: An overview of the interferon system: Signal transduction and mechanisms of action. Cancer Invest 1996;14: 25-53.
2. Viscomi GC, Grimaldi M, Palazzini E, Silvestri S: Human leukocyte interferon alpha: Structure, pharmacology, and therapeutic applications. Med Res Rev 1995;15:445-478.
3. Tanneberger S, Hrelia P: Interferons in pre-cancer and cancer prevention: Where are we? J Interferon Cytokine Res 1996;16:339-346.
4. Dorr RT: Interferon-α in malignant and viral diseases: A review. Drugs 1993;45:177-211.
5. Gutterman JU: Cytokine therapeutics: Lessons from interferon α. Proc Natl Acad Sci USA 1994;91:1198-1205.
6. Tsavaris N, Baxevanis C, Kosmidis P, Papamichael M: The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon α2b. Cancer Immunol Immunother 1996;43:94-102.
7. Haria M, Benfield P: Interferon-α-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995;50:873-896.
8. Carithers RL Jr, Emerson SS: Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials. Hepatology 1997;26:83S-88S.
9. Dusheiko G: Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26: 112S-121S.
10. Iino S, Hino K, Yasuda K: Current state of interferon therapy for chronic hepatitis C. Intervirology 1994;37:87-100.
11. Quin JW: Interferon therapy for acute hepatitis C viral infection - A review by meta-analysis. Aust NZ J Med 1997;27:611-618.
12. Cianchetti C, Marrosu MG, Muntoni F, Fratta A, Zuddas A: Intraventricular α-interferon in subacute sclerosing panencephalitis. Neurology 1998;50:315-316.
13. Gascon G, Yamani S, Crowell J, Stigsby B, Nester M, Kanaan I, Jallu A: Combined oral isoprinosine-intraventricular α-interferon therapy for subacute sclerosing panencephalitis. Brain Dev 1993;15:346-355.
14. Miyazaki M, Hashimolo T, Fujino K, Goda T, Tayama M, Kuroda Y: Apparent response of subacute sclerosing panencephalitis to intrathecal interferon alpha. Ann Neurol 1991;29: 97-99.
15. Tomoda A, Miike T, Miyagawa S, Negi A, Takeshima H: Subacute sclerosing panencephalitis and chorioretinitis. Brain Dev 1997;19: 55-57.
16. Yagi S, Miura Y, Mizuta S, Wakunami A, Kataoka N, Morita T, Morita K, Ono S, Fukunaga M: Chronological SPECT studies of a patient with subacute sclerosing panencephalitis. Brain Dev 1993;15:141-145.
17. Borden EC, Parkinson D: A perspective on the clinical effectiveness and tolerance of interferon-α. Semin Oncol 1998;25(suppl 1):3-8.
18. Gottrand F, Michaud L, Guimber D, Ategbo S, Dubar G, Turck D, Farriaux JP: Influence of recombinant interferon α on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996;155:1031-1034.
19. Meyers CA, Obbens EAMT, Scheibel RS, Moser RP: Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer 1991;68:88-92.
20. Weiss K: Safety profile of interferon-α therapy. Semin Oncol 1998;25(suppl 1):9-13.
21. Plata-Salamán CR: Interferons and central regulation of feeding. Am J Physiol 1992; 263:R1222-R1227.
22. Plata-Salamán CR: Anorexia during acute and chronic disease. Nutrition 1996;12:69-78.
23. Segall MA, Crnic LS: An animal model for the behavioral effects of interferon. Behav Neurosci 1990;104:612-618.
24. Plata-Salamán CR: Immunoregulators in the nervous system. Neurosci Biobehav Rev 1991; 15:185-215.
25. Reyes-Vazquez C, Mendoza-Fernandez V, Herrera-Ruiz M, Dafny N: Interferon modulates glucose-sensitive neurons in the hypothalamus. Exp Brain Res 1997;116:519-524.
26. Reyes-Vázquez C, Prieto-Gómez B, Dafny N: Alpha-interferon suppresses food intake and neuronal activity of the lateral hypothalamus. Neuropharmacology 1994;33:1545-1552.
27. Saphier D, Roerig SC, Ito C, Vlasak WR, Farrar GE, Broyles JE, Welch JE: Inhibition of neural and neuroendocrine activity by α-interferon: Neuroendocrine, electrophysiological, and biochemical studies in the rat. Brain Behav Immun 1994;8:37-56.
28. Kuriyama K, Hori T, Mori T, Nakashima T: Actions of interferona and interleukin-1β on the glucose-responsive neurons in the ventromedial hypothalamus. Brain Res Bull 1990;24: 803-810.
29. Meyers CA, Scheibel RS, Forman AD: Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41:672-676.
30. Memon RA, Feingold KR, Moser AH, Doerrler W, Grunfeld C: In vivo effects of interferon-α and interferon-γ on lipolysis and ketogenesis. Endocrinology 1992;131:1695-1702.
31. Kalra SP: Appetite and body weight regulation: Is it all in the brain? Neuron 1997;19:227-230.
32. Stanley BG, Thomas WJ: Feeding responses to perifornical hypothalamic injection of neuropeptide Y in relation to circadian rhythms of eating behavior. Peptides 1993;14:475-481.
33. Sonti G, Ilyin SE, Plata-Salamán CR: Neuropeptide Y blocks and reverses interleukin-1β-induced anorexia in rats. Peptides 1996;17: 517-520.
34. Jang SH, Lee SH, Ryoo SH, Kim SH, Lee MG: Dose-independent pharmacokinetics of recombinant human interferon-αA in rabbits. Int J Pharmaceutics 1992;84:273-278.
35. Koyanagi S, Ohdo S, Yukawa E, Higuchi S: Chronopharmacological study of interferon-α in mice. J Pharmacol ExpTher 1997;283:259-264.
36. Deprés-Brummer P, Levis F, Di Palma M, Beliard A, Lebon P, Marion S, Jasmin C, Misset J-L: A phase I trial of 21-day continuous venous infusion of α-interferon at circadian rhythm modulated rate in cancer patients. J Immunother 1991;10:440-447.
37. Koren S, Whorton EB Jr, Fleischmann WR Jr: Circadian dependence of interferon antitumor activity in mice. J Natl Cancer Inst 1993;85: 1927-1932.
38. Burtis CA, Ashwood ER: Tietz Textbook of Clinical Chemistry. Philadelphia, Saunders, 1994.
39. Carpenter MB: Core Text of Neuroanatomy. Baltimore, Williams & Wilkins, 1985.
40. McNab BK, Eisenberg JF: Brain size and its relation to the rate of metabolism in mammals. Am Nat 1989;133:157-167.
41. Taylor JL, Grossberg SE: The effects of interferon-α on the production and action of other cytokines. Semin Oncol 1998;25(suppl 1):23-29.
42. Tilg H, Peschel C: Interferon-alpha and its effects on the cytokine cascade: A pro-and anti-inflammatory cytokine. Leuk Lymphoma 1996;23:55-60.
43. Plata-Salamán CR: Cytokines and anorexia: A brief overview. Semin Oncol 1998;25(suppl 1): 64-72.
44. Paez X, Myers RD: Insatiable feeding evoked in rats by recurrent perfusion of neuropeptide Y in the hypothalamus. Peptides 1991;12:609-616.